AU2022249092A1 - Cancer therapy using toll-like receptor agonists - Google Patents

Cancer therapy using toll-like receptor agonists Download PDF

Info

Publication number
AU2022249092A1
AU2022249092A1 AU2022249092A AU2022249092A AU2022249092A1 AU 2022249092 A1 AU2022249092 A1 AU 2022249092A1 AU 2022249092 A AU2022249092 A AU 2022249092A AU 2022249092 A AU2022249092 A AU 2022249092A AU 2022249092 A1 AU2022249092 A1 AU 2022249092A1
Authority
AU
Australia
Prior art keywords
administered
tlr9 agonist
dose
liver
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022249092A
Other languages
English (en)
Other versions
AU2022249092A9 (en
Inventor
Bryan F. COX
David Benjamin Jaroch
Steven C. KATZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trisalus Life Sciences Inc
Original Assignee
Trisalus Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trisalus Life Sciences Inc filed Critical Trisalus Life Sciences Inc
Publication of AU2022249092A1 publication Critical patent/AU2022249092A1/en
Publication of AU2022249092A9 publication Critical patent/AU2022249092A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2022249092A 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists Pending AU2022249092A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169674P 2021-04-01 2021-04-01
US63/169,674 2021-04-01
US202263298589P 2022-01-11 2022-01-11
US63/298,589 2022-01-11
PCT/US2022/022801 WO2022212690A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Publications (2)

Publication Number Publication Date
AU2022249092A1 true AU2022249092A1 (en) 2023-10-12
AU2022249092A9 AU2022249092A9 (en) 2023-10-26

Family

ID=83456830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022249092A Pending AU2022249092A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Country Status (7)

Country Link
EP (1) EP4313315A4 (https=)
JP (1) JP2024512765A (https=)
KR (1) KR20240004419A (https=)
AU (1) AU2022249092A1 (https=)
CA (1) CA3215582A1 (https=)
DE (1) DE112022001882T9 (https=)
WO (1) WO2022212690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024243794A1 (en) * 2023-04-06 2025-11-06 Trisalus Life Sciences, Inc. System and device for providing localized turbulence for delivering a medical embolizing agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US8500775B2 (en) 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
PL3240801T3 (pl) * 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
KR20180014009A (ko) * 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
SG11201808913WA (en) * 2016-04-15 2018-11-29 Dynavax Tech Corp Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US10806893B2 (en) 2017-01-10 2020-10-20 Surefire Medical, Inc. Guiding catheter having shape-retentive distal end
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20190298983A1 (en) 2018-01-15 2019-10-03 Surefire Medical, Inc. Injection Port for Therapeutic Delivery
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
US12433597B2 (en) 2019-06-04 2025-10-07 Trisalus Life Sciences, Inc. Atraumatic occlusive system with compartment for measurement of vascular pressure change
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
IL294621A (en) * 2020-01-10 2022-09-01 Sbi Biotech Co Ltd Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof
CA3196273A1 (en) * 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Also Published As

Publication number Publication date
KR20240004419A (ko) 2024-01-11
AU2022249092A9 (en) 2023-10-26
DE112022001882T5 (de) 2024-01-18
CA3215582A1 (en) 2022-10-06
JP2024512765A (ja) 2024-03-19
WO2022212690A1 (en) 2022-10-06
DE112022001882T9 (de) 2024-02-29
EP4313315A4 (en) 2025-02-19
EP4313315A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP6893608B2 (ja) がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用
US20230364125A1 (en) Cancer therapy using toll-like receptor agonists
US20240180952A1 (en) Cancer therapy using toll-like receptor agonists
AU2022249092A9 (en) Cancer therapy using toll-like receptor agonists
US20230374523A1 (en) Cancer therapy using toll-like receptor agonists
HK40107087A (zh) 使用toll样受体激动剂的癌症疗法
US20250101438A1 (en) Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
CN116685330A (zh) 使用toll样受体激动剂的癌症疗法
HK40100192A (zh) 使用toll样受体激动剂的癌症疗法
HK40096714A (zh) 使用toll样受体激动剂的癌症疗法
CA3218244A1 (en) Cancer therapy using checkpoint inhibitors
CN121729429A (zh) 用一种或多种检查点抑制剂和toll样受体9激动剂的治疗有效组合治疗葡萄膜黑色素瘤肝转移的方法
WO2025096686A1 (en) Methods of treating pancreatic ductal adenocarcinoma with a toll-like receptor 9 agonist

Legal Events

Date Code Title Description
SREP Specification republished